Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
In the GLOW study, fixed-duration ibrutinib–venetoclax showed superior progression-free survival versus chlorambucil–obinutuzumab in patients with previously untreated chronic lymphocytic leukaemia who were older or had comorbidities, or both, at a median follow up of 27·7 months. In this Article, w...
Saved in:
| Published in | The lancet oncology Vol. 24; no. 12; pp. 1423 - 1433 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.12.2023
Elsevier Limited Elsevier |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | In the GLOW study, fixed-duration ibrutinib–venetoclax showed superior progression-free survival versus chlorambucil–obinutuzumab in patients with previously untreated chronic lymphocytic leukaemia who were older or had comorbidities, or both, at a median follow up of 27·7 months. In this Article, we report updated outcomes from GLOW after a 46-month median follow-up.
GLOW was a randomised, multicentre, phase 3 study done at 67 hospital centres across 14 countries. Patients aged 65 years and older or 18–64 years with previously untreated chronic lymphocytic leukaemia and a cumulative illness rating scale score of more than 6 or creatinine clearance less than 70 mL/min, or both, and an Eastern Cooperative Oncology Group performance status of 2 or less were randomly assigned (1:1) via an interactive web system with permuted blocks (block size of four) and stratified by IGHV mutational status and the presence of del11q aberration to the ibrutinib–venetoclax group (three cycles of ibrutinib lead-in [420 mg/day, orally], followed by 12 cycles of ibrutinib plus venetoclax [400 mg/day, orally, including a 5-week dose ramp-up]) or the chlorambucil–obinutuzumab group (six cycles of chlorambucil [0·5 mg/kg, orally, on days 1 and 15 of each cycle], and obinutuzumab [1000 mg, intravenously, on days 1 (or 100 mg on day 1 and 900 mg on day 2), 8, and 15 of cycle 1 and day 1 of cycles 2–6]). The primary endpoint was progression-free survival in the intention-to-treat population, assessed by an independent review committee. The safety population included all randomised patients who received at least one dose of the study treatment. This study is registered with ClinicalTrials.gov (NCT03462719) and the EU Clinical Trials Register (EudraCT 2017-004699-77).
Between May 4, 2018, and April 5, 2019, 211 patients (122 [58%] were male and 89 [42%] were female) were randomly assigned to receive ibrutinib–venetoclax (n=106) or chlorambucil–obinutuzumab (n=105). At a median of 46 months (IQR 43–47) of follow-up, progression-free survival remained superior for the ibrutinib–venetoclax group (hazard ratio 0·214 [95% CI 0·138–0·334]; p<0·0001); 42-month progression-free survival rates were 74·6% (95% CI 65·0–82·0) for ibrutinib–venetoclax and 24·8% (16·5–34·1) for chlorambucil–obinutuzumab. Following the primary analysis, one patient in the chlorambucil–obinutuzumab group had a serious adverse event of myelodysplastic syndrome. Treatment-related deaths were reported in one patient receiving ibrutinib–venetoclax (cardiac failure, pneumonia, and sinus node dysfunction) and in one patient receiving chlorambucil–obinutuzumab (pneumonia). There were 15 deaths in the ibrutinib–venetoclax group (of which three were due to post-treatment infections) and 30 deaths in the chlorambucil–obinutuzumab group (of which 10 were due to post-treatment infections).
After 4 years of follow-up, ibrutinib–venetoclax continues to significantly prolong progression-free survival (vs chemoimmunotherapy) in patients with previously untreated chronic lymphocytic leukaemia, supporting its use as a first-line option.
Janssen Research & Development and Pharmacyclics. |
|---|---|
| AbstractList | In the GLOW study, fixed-duration ibrutinib-venetoclax showed superior progression-free survival versus chlorambucil-obinutuzumab in patients with previously untreated chronic lymphocytic leukaemia who were older or had comorbidities, or both, at a median follow up of 27·7 months. In this Article, we report updated outcomes from GLOW after a 46-month median follow-up.
GLOW was a randomised, multicentre, phase 3 study done at 67 hospital centres across 14 countries. Patients aged 65 years and older or 18-64 years with previously untreated chronic lymphocytic leukaemia and a cumulative illness rating scale score of more than 6 or creatinine clearance less than 70 mL/min, or both, and an Eastern Cooperative Oncology Group performance status of 2 or less were randomly assigned (1:1) via an interactive web system with permuted blocks (block size of four) and stratified by IGHV mutational status and the presence of del11q aberration to the ibrutinib-venetoclax group (three cycles of ibrutinib lead-in [420 mg/day, orally], followed by 12 cycles of ibrutinib plus venetoclax [400 mg/day, orally, including a 5-week dose ramp-up]) or the chlorambucil-obinutuzumab group (six cycles of chlorambucil [0·5 mg/kg, orally, on days 1 and 15 of each cycle], and obinutuzumab [1000 mg, intravenously, on days 1 (or 100 mg on day 1 and 900 mg on day 2), 8, and 15 of cycle 1 and day 1 of cycles 2-6]). The primary endpoint was progression-free survival in the intention-to-treat population, assessed by an independent review committee. The safety population included all randomised patients who received at least one dose of the study treatment. This study is registered with ClinicalTrials.gov (NCT03462719) and the EU Clinical Trials Register (EudraCT 2017-004699-77).
Between May 4, 2018, and April 5, 2019, 211 patients (122 [58%] were male and 89 [42%] were female) were randomly assigned to receive ibrutinib-venetoclax (n=106) or chlorambucil-obinutuzumab (n=105). At a median of 46 months (IQR 43-47) of follow-up, progression-free survival remained superior for the ibrutinib-venetoclax group (hazard ratio 0·214 [95% CI 0·138-0·334]; p<0·0001); 42-month progression-free survival rates were 74·6% (95% CI 65·0-82·0) for ibrutinib-venetoclax and 24·8% (16·5-34·1) for chlorambucil-obinutuzumab. Following the primary analysis, one patient in the chlorambucil-obinutuzumab group had a serious adverse event of myelodysplastic syndrome. Treatment-related deaths were reported in one patient receiving ibrutinib-venetoclax (cardiac failure, pneumonia, and sinus node dysfunction) and in one patient receiving chlorambucil-obinutuzumab (pneumonia). There were 15 deaths in the ibrutinib-venetoclax group (of which three were due to post-treatment infections) and 30 deaths in the chlorambucil-obinutuzumab group (of which 10 were due to post-treatment infections).
After 4 years of follow-up, ibrutinib-venetoclax continues to significantly prolong progression-free survival (vs chemoimmunotherapy) in patients with previously untreated chronic lymphocytic leukaemia, supporting its use as a first-line option.
Janssen Research & Development and Pharmacyclics. Summary Background In the GLOW study, fixed-duration ibrutinib–venetoclax showed superior progression-free survival versus chlorambucil–obinutuzumab in patients with previously untreated chronic lymphocytic leukaemia who were older or had comorbidities, or both, at a median follow up of 27·7 months. In this Article, we report updated outcomes from GLOW after a 46-month median follow-up. Methods GLOW was a randomised, multicentre, phase 3 study done at 67 hospital centres across 14 countries. Patients aged 65 years and older or 18–64 years with previously untreated chronic lymphocytic leukaemia and a cumulative illness rating scale score of more than 6 or creatinine clearance less than 70 mL/min, or both, and an Eastern Cooperative Oncology Group performance status of 2 or less were randomly assigned (1:1) via an interactive web system with permuted blocks (block size of four) and stratified by IGHV mutational status and the presence of del11q aberration to the ibrutinib–venetoclax group (three cycles of ibrutinib lead-in [420 mg/day, orally], followed by 12 cycles of ibrutinib plus venetoclax [400 mg/day, orally, including a 5-week dose ramp-up]) or the chlorambucil–obinutuzumab group (six cycles of chlorambucil [0·5 mg/kg, orally, on days 1 and 15 of each cycle], and obinutuzumab [1000 mg, intravenously, on days 1 (or 100 mg on day 1 and 900 mg on day 2), 8, and 15 of cycle 1 and day 1 of cycles 2–6]). The primary endpoint was progression-free survival in the intention-to-treat population, assessed by an independent review committee. The safety population included all randomised patients who received at least one dose of the study treatment. This study is registered with ClinicalTrials.gov (NCT03462719) and the EU Clinical Trials Register (EudraCT 2017-004699-77). Findings Between May 4, 2018, and April 5, 2019, 211 patients (122 [58%] were male and 89 [42%] were female) were randomly assigned to receive ibrutinib–venetoclax (n=106) or chlorambucil–obinutuzumab (n=105). At a median of 46 months (IQR 43–47) of follow-up, progression-free survival remained superior for the ibrutinib–venetoclax group (hazard ratio 0·214 [95% CI 0·138–0·334]; p<0·0001); 42-month progression-free survival rates were 74·6% (95% CI 65·0–82·0) for ibrutinib–venetoclax and 24·8% (16·5–34·1) for chlorambucil–obinutuzumab. Following the primary analysis, one patient in the chlorambucil–obinutuzumab group had a serious adverse event of myelodysplastic syndrome. Treatment-related deaths were reported in one patient receiving ibrutinib–venetoclax (cardiac failure, pneumonia, and sinus node dysfunction) and in one patient receiving chlorambucil–obinutuzumab (pneumonia). There were 15 deaths in the ibrutinib–venetoclax group (of which three were due to post-treatment infections) and 30 deaths in the chlorambucil–obinutuzumab group (of which 10 were due to post-treatment infections). Interpretation After 4 years of follow-up, ibrutinib–venetoclax continues to significantly prolong progression-free survival (vs chemoimmunotherapy) in patients with previously untreated chronic lymphocytic leukaemia, supporting its use as a first-line option. Funding Janssen Research & Development and Pharmacyclics. BackgroundIn the GLOW study, fixed-duration ibrutinib-venetoclax showed superior progression-free survival versus chlorambucil-obinutuzumab in patients with previously untreated chronic lymphocytic leukaemia who were older or had comorbidities, or both, at a median follow up of 27•7 months. In this Article, we report updated outcomes from GLOW after a 46-month median follow-up. MethodsGLOW was a randomised, multicentre, phase 3 study done at 67 hospital centres across 14 countries. Patients aged 65 years and older or 18-64 years with previously untreated chronic lymphocytic leukaemia and a cumulative illness rating scale score of more than 6 or creatinine clearance less than 70 mL/min, or both, and an Eastern Cooperative Oncology Group performance status of 2 or less were randomly assigned (1:1) via an interactive web system with permuted blocks (block size of four) and stratified by IGHV mutational status and the presence of del11q aberration to the ibrutinib-venetoclax group (three cycles of ibrutinib lead-in [420 mg/day, orally], followed by 12 cycles of ibrutinib plus venetoclax [400 mg/day, orally, including a 5-week dose ramp-up]) or the chlorambucilobinutuzumab group (six cycles of chlorambucil [0•5 mg/kg, orally, on days 1 and 15 of each cycle], and obinutuzumab [1000 mg, intravenously, on days 1 (or 100 mg on day 1 and 900 mg on day 2), 8, and 15 of cycle 1 and day 1 of cycles 2-6]). The primary endpoint was progression-free survival in the intention-to-treat population, assessed by an independent review committee. The safety population included all randomised patients who received at least one dose of the study treatment. This study is registered with ClinicalTrials.gov (NCT03462719) and the EU Clinical Trials Register (EudraCT 2017-004699-77). Findings Between May 4, 2018, and April 5, 2019, 211 patients (122 [58%] were male and 89 [42%] were female) were randomly assigned to receive ibrutinib-venetoclax (n=106) or chlorambucil-obinutuzumab (n=105). At a median of 46 months (IQR 43-47) of follow-up, progression-free survival remained superior for the ibrutinib-venetoclax group (hazard ratio 0•214 [95% CI 0•138-0•334]; p<0•0001); 42-month progression-free survival rates were 74•6% (95% CI 65•0-82•0) for ibrutinib-venetoclax and 24•8% (16•5-34•1) for chlorambucil-obinutuzumab. Following the primary analysis, one patient in the chlorambucil-obinutuzumab group had a serious adverse event of myelodysplastic syndrome. Treatment-related deaths were reported in one patient receiving ibrutinib-venetoclax (cardiac failure, pneumonia, and sinus node dysfunction) and in one patient receiving chlorambucil-obinutuzumab (pneumonia). There were 15 deaths in the ibrutinib-venetoclax group (of which three were due to post-treatment infections) and 30 deaths in the chlorambucil-obinutuzumab group (of which 10 were due to post-treatment infections).Interpretation After 4 years of follow-up, ibrutinib-venetoclax continues to significantly prolong progression-free survival (vs chemoimmunotherapy) in patients with previously untreated chronic lymphocytic leukaemia, supporting its use as a first-line option. In the GLOW study, fixed-duration ibrutinib-venetoclax showed superior progression-free survival versus chlorambucil-obinutuzumab in patients with previously untreated chronic lymphocytic leukaemia who were older or had comorbidities, or both, at a median follow up of 27·7 months. In this Article, we report updated outcomes from GLOW after a 46-month median follow-up.BACKGROUNDIn the GLOW study, fixed-duration ibrutinib-venetoclax showed superior progression-free survival versus chlorambucil-obinutuzumab in patients with previously untreated chronic lymphocytic leukaemia who were older or had comorbidities, or both, at a median follow up of 27·7 months. In this Article, we report updated outcomes from GLOW after a 46-month median follow-up.GLOW was a randomised, multicentre, phase 3 study done at 67 hospital centres across 14 countries. Patients aged 65 years and older or 18-64 years with previously untreated chronic lymphocytic leukaemia and a cumulative illness rating scale score of more than 6 or creatinine clearance less than 70 mL/min, or both, and an Eastern Cooperative Oncology Group performance status of 2 or less were randomly assigned (1:1) via an interactive web system with permuted blocks (block size of four) and stratified by IGHV mutational status and the presence of del11q aberration to the ibrutinib-venetoclax group (three cycles of ibrutinib lead-in [420 mg/day, orally], followed by 12 cycles of ibrutinib plus venetoclax [400 mg/day, orally, including a 5-week dose ramp-up]) or the chlorambucil-obinutuzumab group (six cycles of chlorambucil [0·5 mg/kg, orally, on days 1 and 15 of each cycle], and obinutuzumab [1000 mg, intravenously, on days 1 (or 100 mg on day 1 and 900 mg on day 2), 8, and 15 of cycle 1 and day 1 of cycles 2-6]). The primary endpoint was progression-free survival in the intention-to-treat population, assessed by an independent review committee. The safety population included all randomised patients who received at least one dose of the study treatment. This study is registered with ClinicalTrials.gov (NCT03462719) and the EU Clinical Trials Register (EudraCT 2017-004699-77).METHODSGLOW was a randomised, multicentre, phase 3 study done at 67 hospital centres across 14 countries. Patients aged 65 years and older or 18-64 years with previously untreated chronic lymphocytic leukaemia and a cumulative illness rating scale score of more than 6 or creatinine clearance less than 70 mL/min, or both, and an Eastern Cooperative Oncology Group performance status of 2 or less were randomly assigned (1:1) via an interactive web system with permuted blocks (block size of four) and stratified by IGHV mutational status and the presence of del11q aberration to the ibrutinib-venetoclax group (three cycles of ibrutinib lead-in [420 mg/day, orally], followed by 12 cycles of ibrutinib plus venetoclax [400 mg/day, orally, including a 5-week dose ramp-up]) or the chlorambucil-obinutuzumab group (six cycles of chlorambucil [0·5 mg/kg, orally, on days 1 and 15 of each cycle], and obinutuzumab [1000 mg, intravenously, on days 1 (or 100 mg on day 1 and 900 mg on day 2), 8, and 15 of cycle 1 and day 1 of cycles 2-6]). The primary endpoint was progression-free survival in the intention-to-treat population, assessed by an independent review committee. The safety population included all randomised patients who received at least one dose of the study treatment. This study is registered with ClinicalTrials.gov (NCT03462719) and the EU Clinical Trials Register (EudraCT 2017-004699-77).Between May 4, 2018, and April 5, 2019, 211 patients (122 [58%] were male and 89 [42%] were female) were randomly assigned to receive ibrutinib-venetoclax (n=106) or chlorambucil-obinutuzumab (n=105). At a median of 46 months (IQR 43-47) of follow-up, progression-free survival remained superior for the ibrutinib-venetoclax group (hazard ratio 0·214 [95% CI 0·138-0·334]; p<0·0001); 42-month progression-free survival rates were 74·6% (95% CI 65·0-82·0) for ibrutinib-venetoclax and 24·8% (16·5-34·1) for chlorambucil-obinutuzumab. Following the primary analysis, one patient in the chlorambucil-obinutuzumab group had a serious adverse event of myelodysplastic syndrome. Treatment-related deaths were reported in one patient receiving ibrutinib-venetoclax (cardiac failure, pneumonia, and sinus node dysfunction) and in one patient receiving chlorambucil-obinutuzumab (pneumonia). There were 15 deaths in the ibrutinib-venetoclax group (of which three were due to post-treatment infections) and 30 deaths in the chlorambucil-obinutuzumab group (of which 10 were due to post-treatment infections).FINDINGSBetween May 4, 2018, and April 5, 2019, 211 patients (122 [58%] were male and 89 [42%] were female) were randomly assigned to receive ibrutinib-venetoclax (n=106) or chlorambucil-obinutuzumab (n=105). At a median of 46 months (IQR 43-47) of follow-up, progression-free survival remained superior for the ibrutinib-venetoclax group (hazard ratio 0·214 [95% CI 0·138-0·334]; p<0·0001); 42-month progression-free survival rates were 74·6% (95% CI 65·0-82·0) for ibrutinib-venetoclax and 24·8% (16·5-34·1) for chlorambucil-obinutuzumab. Following the primary analysis, one patient in the chlorambucil-obinutuzumab group had a serious adverse event of myelodysplastic syndrome. Treatment-related deaths were reported in one patient receiving ibrutinib-venetoclax (cardiac failure, pneumonia, and sinus node dysfunction) and in one patient receiving chlorambucil-obinutuzumab (pneumonia). There were 15 deaths in the ibrutinib-venetoclax group (of which three were due to post-treatment infections) and 30 deaths in the chlorambucil-obinutuzumab group (of which 10 were due to post-treatment infections).After 4 years of follow-up, ibrutinib-venetoclax continues to significantly prolong progression-free survival (vs chemoimmunotherapy) in patients with previously untreated chronic lymphocytic leukaemia, supporting its use as a first-line option.INTERPRETATIONAfter 4 years of follow-up, ibrutinib-venetoclax continues to significantly prolong progression-free survival (vs chemoimmunotherapy) in patients with previously untreated chronic lymphocytic leukaemia, supporting its use as a first-line option.Janssen Research & Development and Pharmacyclics.FUNDINGJanssen Research & Development and Pharmacyclics. |
| Author | Munir, Talha Voloshin, Sergey Baeten, Kurt Caces, Donne Bennett Robak, Tadeusz Ysebaert, Loic Qi, Qianya Schuier, Natasha Parisi, Lori Qi, Keqin Srinivasan, Srimathi Niemann, Carsten U Moreno, Carol Benjamini, Ohad Simkovic, Martin Levin, Mark-David Owen, Carolyn Janssens, Ann Kater, Arnon P Yagci, Munci Howes, Angela Sinet, Pierre Vorobyev, Vladimir Follows, George A |
| Author_xml | – sequence: 1 givenname: Carsten U surname: Niemann fullname: Niemann, Carsten U email: carsten.utoft.niemann@regionh.dk organization: Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark – sequence: 2 givenname: Talha surname: Munir fullname: Munir, Talha organization: St James's Hospital, Leeds, UK – sequence: 3 givenname: Carol surname: Moreno fullname: Moreno, Carol organization: Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Josep Carreras Leukaemia Research Institute, Barcelona, Spain – sequence: 4 givenname: Carolyn surname: Owen fullname: Owen, Carolyn organization: Tom Baker Cancer Centre, Calgary, AB, Canada – sequence: 5 givenname: George A surname: Follows fullname: Follows, George A organization: Addenbrookes Hospital, Cambridge, UK – sequence: 6 givenname: Ohad surname: Benjamini fullname: Benjamini, Ohad organization: Sheba Medical Center, Ramat Gan, Israel – sequence: 7 givenname: Ann surname: Janssens fullname: Janssens, Ann organization: UZ Leuven Gasthuisberg, Leuven, Belgium – sequence: 8 givenname: Mark-David surname: Levin fullname: Levin, Mark-David organization: Albert Schweitzer Hospital, Dordrecht, Netherlands – sequence: 9 givenname: Tadeusz surname: Robak fullname: Robak, Tadeusz organization: Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland – sequence: 10 givenname: Martin surname: Simkovic fullname: Simkovic, Martin organization: 4th Department of Internal Medicine–Haematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Hradec Králové, Czech Republic – sequence: 11 givenname: Sergey surname: Voloshin fullname: Voloshin, Sergey organization: Russian Scientific and Research Institute of Hematology and Transfusiology, St Petersburg, Russia – sequence: 12 givenname: Vladimir surname: Vorobyev fullname: Vorobyev, Vladimir organization: SP Botkin Moscow City Clinical Hospital, Moscow, Russia – sequence: 13 givenname: Munci surname: Yagci fullname: Yagci, Munci organization: Gazi Universitesi Tip Fakultesi, Ankara, Türkiye – sequence: 14 givenname: Loic surname: Ysebaert fullname: Ysebaert, Loic organization: Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France – sequence: 15 givenname: Keqin surname: Qi fullname: Qi, Keqin organization: Janssen Research & Development, Titusville, NJ, USA – sequence: 16 givenname: Qianya surname: Qi fullname: Qi, Qianya organization: Janssen Research & Development, Raritan, NJ, USA – sequence: 17 givenname: Pierre surname: Sinet fullname: Sinet, Pierre organization: Janssen Research & Development, Bridgewater, NJ, USA – sequence: 18 givenname: Lori surname: Parisi fullname: Parisi, Lori organization: Janssen Research & Development, Raritan, NJ, USA – sequence: 19 givenname: Srimathi surname: Srinivasan fullname: Srinivasan, Srimathi organization: Oncology Translational Research, Janssen Research & Development, Lower Gwynedd Township, PA, USA – sequence: 20 givenname: Natasha surname: Schuier fullname: Schuier, Natasha organization: Janssen Research & Development, Raritan, NJ, USA – sequence: 21 givenname: Kurt surname: Baeten fullname: Baeten, Kurt organization: Janssen Research & Development, Beerse, Belgium – sequence: 22 givenname: Angela surname: Howes fullname: Howes, Angela organization: Janssen Research & Development, High Wycombe, UK – sequence: 23 givenname: Donne Bennett surname: Caces fullname: Caces, Donne Bennett organization: Janssen Research & Development, Raritan, NJ, USA – sequence: 24 givenname: Arnon P surname: Kater fullname: Kater, Arnon P organization: Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, Netherlands |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37944541$$D View this record in MEDLINE/PubMed https://inserm.hal.science/inserm-04777948$$DView record in HAL |
| BookMark | eNqFks1u1DAUhSNURH_gEUCW2EylCdiJPU7YoKrqD9JIXQBiadnOjcbFsYMdDx1WfQeejFfgSfDMlC7YsLpX1neur4_PcXHgvIOieEnwG4LJ4u1HQjkuK0zZrKpPca5VyZ8UR_mYlow2zcGu3yOHxXGMtxgTTjB7VhzWvKWUUXJU_Lo0d9CVXQpyMt4ho0KajDPq9_3PNTiYvLbyDq0hxBSRXlkf5KCSNjYDXhmXpvQjDVIh49AYYG18inaDkpsCyAm6rAneGY3sZhhXXm-mbQ_pq4TBSDS7Wt58OX2HaLkBGVDvrfXfyzSiPvgBSTQkmwWwnTZHfgRXWqnAzlGQrvODidDN0biSEVCNpmCkfV487aWN8OKhnhSfLy8-nV-Xy5urD-dny1LTGk-lwtBWoGsOChSV9aIhVccYr0nFKdNSMw2M40aSHmSLO441V63iXFbQU63rk2K-n7uSVozBDDJshJdGXJ8thXERwiAw5Txb3axJxmd7fAz-W4I4iby8Bmulg2yZqJqmrShrGM3o63_QW5-Cy4_JVEsXLeMcZ4rtKR18jAH6xyUIFtuIiF1ExPb_RVWLXUQEz7pXD9OTGqB7VP3NRAbe7wHI7q0NBBG1AaehMwH0JDpv_nPFH84j05Y |
| CitedBy_id | crossref_primary_10_3390_cancers16112049 crossref_primary_10_1080_17425255_2024_2334322 crossref_primary_10_1182_blood_2024024877 crossref_primary_10_1016_j_critrevonc_2024_104408 crossref_primary_10_1080_17474086_2024_2366534 crossref_primary_10_1007_s00277_024_05666_3 crossref_primary_10_1016_S1470_2045_23_00485_0 crossref_primary_10_1016_S1470_2045_23_00620_4 crossref_primary_10_1016_S1470_2045_23_00677_0 crossref_primary_10_3390_cancers16111996 crossref_primary_10_3390_cancers16061228 crossref_primary_10_3390_cancers16071290 crossref_primary_10_1016_j_clml_2024_05_019 crossref_primary_10_1053_j_seminhematol_2024_01_015 crossref_primary_10_1016_S1470_2045_24_00024_X |
| Cites_doi | 10.1056/NEJMoa1812836 10.1200/JCO.19.00894 10.1016/S1470-2045(23)00144-4 10.1182/blood-2017-09-806398 10.1056/NEJMoa1900574 10.1182/bloodadvances.2021004861 10.1002/ajh.25638 10.1200/JCO.21.00807 10.1002/hon.2828 10.1182/bloodadvances.2021006434 10.1016/j.leukres.2021.106520 10.1016/S1470-2045(22)00220-0 10.1200/JCO.22.02283 10.1016/S0140-6736(20)30262-2 10.1097/01.HS9.0000969372.28228.42 10.1177/2040620721989588 10.1016/j.bcmd.2020.102525 10.1038/s43856-022-00178-5 10.1182/blood.2021014488 10.3324/haematol.2021.279012 10.1182/blood.2021014960 10.1200/JCO.21.01181 10.1038/s41408-021-00429-z 10.1097/HS9.0000000000000811 10.1182/blood-2022-163209 10.1056/NEJMoa1313984 10.1056/EVIDoa2200006 |
| ContentType | Journal Article |
| Copyright | 2023 Elsevier Ltd Copyright © 2023 Elsevier Ltd. All rights reserved. 2023. Elsevier Ltd Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: 2023 Elsevier Ltd – notice: Copyright © 2023 Elsevier Ltd. All rights reserved. – notice: 2023. Elsevier Ltd – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 0TZ 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PQEST PQQKQ PQUKI PRINS 7X8 1XC VOOES |
| DOI | 10.1016/S1470-2045(23)00452-7 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Pharma and Biotech Premium PRO ProQuest Central (Corporate) ProQuest Nursing and Allied Health Journals Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database (Proquest) Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Medical Database Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Pharma and Biotech Premium PRO Oncogenes and Growth Factors Abstracts Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) AIDS and Cancer Research Abstracts ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Pharma and Biotech Premium PRO MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | 1433 |
| ExternalDocumentID | oai_HAL_inserm_04777948v1 10_1016_S1470_2045_23_00452_7 37944541 S1470204523004527 |
| Genre | Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation | Janssen Research & Development and Pharmacyclics. |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 3V. 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAQFI AAQQT AAQXK AAWTL AAXUO ABBQC ABLVK ABMAC ABMZM ABUWG ABYKQ ACGFS ACPRK ACRLP ADBBV ADMUD AEKER AENEX AEVXI AFKRA AFKWA AFRHN AFTJW AFXIZ AGHFR AHMBA AITUG AJBFU AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AQVPL ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM LCYCR M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PQQKQ PROAC PSQYO R2- RIG ROL RPZ SDF SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R ZA5 AAMRU AAXKI AFCTW ALIPV CGR CUY CVF ECM EIF NPM AAYXX ACRPL CITATION 0TZ 7TO 7XB 8FK H94 K9. PQEST PQUKI PRINS 7X8 1XC ABWVN ADNMO VOOES |
| ID | FETCH-LOGICAL-c430t-b0e92ec37ebeb4a36812d557312745cac5ce5708a1fea90d70c7b9b77a2ef4cc3 |
| IEDL.DBID | 8C1 |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Wed Dec 18 07:34:11 EST 2024 Thu Dec 05 23:05:20 EST 2024 Thu Oct 10 21:13:56 EDT 2024 Fri Dec 06 00:39:08 EST 2024 Sat Nov 02 12:10:06 EDT 2024 Sat Apr 13 16:38:42 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| License | Copyright © 2023 Elsevier Ltd. All rights reserved. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c430t-b0e92ec37ebeb4a36812d557312745cac5ce5708a1fea90d70c7b9b77a2ef4cc3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| OpenAccessLink | https://inserm.hal.science/inserm-04777948 |
| PMID | 37944541 |
| PQID | 2894695770 |
| PQPubID | 46089 |
| PageCount | 11 |
| ParticipantIDs | hal_primary_oai_HAL_inserm_04777948v1 proquest_miscellaneous_2889245854 proquest_journals_2894695770 crossref_primary_10_1016_S1470_2045_23_00452_7 pubmed_primary_37944541 elsevier_sciencedirect_doi_10_1016_S1470_2045_23_00452_7 |
| PublicationCentury | 2000 |
| PublicationDate | December 2023 2023-12-00 20231201 2023-12 |
| PublicationDateYYYYMMDD | 2023-12-01 |
| PublicationDate_xml | – month: 12 year: 2023 text: December 2023 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2023 |
| Publisher | Elsevier Ltd Elsevier Limited Elsevier |
| Publisher_xml | – sequence: 0 name: Elsevier – name: Elsevier Ltd – name: Elsevier Limited |
| References | Borah, Mirgh, Sharma (bib28) 2021; 87 (bib17) March 26, 2018 Shadman, Liu, Eakle (bib29) 2022; 7 Amitai, Gafter-Gvili, Shargian-Alon, Raanani, Gurion (bib9) 2021; 39 Sharman, Egyed, Jurczak (bib25) 2020; 395 Ghia P, Owen C, Barrientos JC, et al. Initiating first-line ibrutinib in patients with chronic lymphocytic leukemia (CLL) improves overall survival outcomes to rates approximating an age-matched population of ≥65 years. 64th Annual American Society of Hematology (ASH) Meeting & Exposition; Dec 10–13, 2022 (poster 1809). Munir, Moreno, Owen (bib19) 2023; 41 Hillmen, Pitchford, Bloor (bib21) 2023; 24 Barr, Owen, Robak (bib2) 2022; 6 Al-Sawaf, Zhang, Lu (bib8) 2021; 39 Woyach, Ruppert, Heerema (bib7) 2018; 379 Lu, Wang, Franzen (bib10) 2021; 11 Jain, Keating, Thompson (bib14) 2019; 380 Solman, Blum, Burger (bib27) 2021; 102 Wierda, Allan, Siddiqi (bib12) 2021; 39 Shanafelt, Wang, Hanson (bib5) 2022; 140 Kater, Levin, Dubois (bib16) 2022; 23 Goede, Fischer, Busch (bib24) 2014; 370 Hallek, Cheson, Catovsky (bib20) 2018; 131 Moreno, Greil, Demirkan (bib6) 2022; 107 Tam, Allan, Siddiqi (bib15) 2022; 139 Svanberg, MacPherson, Zucco (bib26) 2022; 2 Hillmen, Rawstron, Brock (bib13) 2019; 37 Munir, Brown, O'Brien (bib4) 2019; 94 Kater, Owen, Moreno (bib18) 2022; 1 Wierda WG, Barr PM, Siddiqi T, et al. Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma: 3-year follow-up from the FD cohort of the phase 2 CAPTIVATE study. ASCO Annual Meeting; June 3–7, 2022 (poster 7519). Levin, Kersting, Dubois (bib22) 2022; 140 Gordon, Danilov (bib1) 2021; 12 Kater, Slinger, Cretenet (bib11) 2021; 5 37944540 - Lancet Oncol. 2023 Dec;24(12):1294-1295. doi: 10.1016/S1470-2045(23)00485-0 Jain (10.1016/S1470-2045(23)00452-7_bib14) 2019; 380 Amitai (10.1016/S1470-2045(23)00452-7_bib9) 2021; 39 Svanberg (10.1016/S1470-2045(23)00452-7_bib26) 2022; 2 Kater (10.1016/S1470-2045(23)00452-7_bib16) 2022; 23 Munir (10.1016/S1470-2045(23)00452-7_bib4) 2019; 94 Hillmen (10.1016/S1470-2045(23)00452-7_bib13) 2019; 37 Shadman (10.1016/S1470-2045(23)00452-7_bib29) 2022; 7 Levin (10.1016/S1470-2045(23)00452-7_bib22) 2022; 140 Hallek (10.1016/S1470-2045(23)00452-7_bib20) 2018; 131 Hillmen (10.1016/S1470-2045(23)00452-7_bib21) 2023; 24 Woyach (10.1016/S1470-2045(23)00452-7_bib7) 2018; 379 Wierda (10.1016/S1470-2045(23)00452-7_bib12) 2021; 39 Goede (10.1016/S1470-2045(23)00452-7_bib24) 2014; 370 Solman (10.1016/S1470-2045(23)00452-7_bib27) 2021; 102 Lu (10.1016/S1470-2045(23)00452-7_bib10) 2021; 11 Munir (10.1016/S1470-2045(23)00452-7_bib19) 2023; 41 Borah (10.1016/S1470-2045(23)00452-7_bib28) 2021; 87 10.1016/S1470-2045(23)00452-7_bib3 Kater (10.1016/S1470-2045(23)00452-7_bib11) 2021; 5 Tam (10.1016/S1470-2045(23)00452-7_bib15) 2022; 139 Shanafelt (10.1016/S1470-2045(23)00452-7_bib5) 2022; 140 Sharman (10.1016/S1470-2045(23)00452-7_bib25) 2020; 395 Gordon (10.1016/S1470-2045(23)00452-7_bib1) 2021; 12 Kater (10.1016/S1470-2045(23)00452-7_bib18) 2022; 1 Barr (10.1016/S1470-2045(23)00452-7_bib2) 2022; 6 Moreno (10.1016/S1470-2045(23)00452-7_bib6) 2022; 107 10.1016/S1470-2045(23)00452-7_bib23 Al-Sawaf (10.1016/S1470-2045(23)00452-7_bib8) 2021; 39 |
| References_xml | – volume: 2 start-page: 114 year: 2022 ident: bib26 article-title: Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients publication-title: Commun Med (Lond) contributor: fullname: Zucco – volume: 140 start-page: 4137 year: 2022 end-page: 4139 ident: bib22 article-title: Exploratory results of PET-CT and residual lymph node fine needle aspiration of patients treated with first-line venetoclax and ibrutinib for CLL/Sll; first interim analysis of the phase 2 HOVON 158/Next STEP trial publication-title: Blood contributor: fullname: Dubois – volume: 39 start-page: 4049 year: 2021 end-page: 4060 ident: bib8 article-title: Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study publication-title: J Clin Oncol contributor: fullname: Lu – volume: 379 start-page: 2517 year: 2018 end-page: 2528 ident: bib7 article-title: Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL publication-title: N Engl J Med contributor: fullname: Heerema – volume: 6 start-page: 3440 year: 2022 end-page: 3450 ident: bib2 article-title: Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia publication-title: Blood Adv contributor: fullname: Robak – volume: 39 start-page: 215 year: 2021 end-page: 221 ident: bib9 article-title: Obinutuzumab-related adverse events: a systematic review and meta-analysis publication-title: Hematol Oncol contributor: fullname: Gurion – volume: 7 start-page: e811 year: 2022 ident: bib29 article-title: COVID-19 vaccination response and its practical application in patients with chronic lymphocytic leukemia publication-title: HemaSphere contributor: fullname: Eakle – volume: 94 start-page: 1353 year: 2019 end-page: 1363 ident: bib4 article-title: Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma publication-title: Am J Hematol contributor: fullname: O'Brien – volume: 370 start-page: 1101 year: 2014 end-page: 1110 ident: bib24 article-title: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions publication-title: N Engl J Med contributor: fullname: Busch – volume: 102 year: 2021 ident: bib27 article-title: Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia publication-title: Leuk Res contributor: fullname: Burger – volume: 23 start-page: 818 year: 2022 end-page: 828 ident: bib16 article-title: Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial publication-title: Lancet Oncol contributor: fullname: Dubois – volume: 380 start-page: 2095 year: 2019 end-page: 2103 ident: bib14 article-title: Ibrutinib and venetoclax for first-line treatment of CLL publication-title: N Engl J Med contributor: fullname: Thompson – volume: 1 year: 2022 ident: bib18 article-title: Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities publication-title: NEJM Evid contributor: fullname: Moreno – volume: 131 start-page: 2745 year: 2018 end-page: 2760 ident: bib20 article-title: iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL publication-title: Blood contributor: fullname: Catovsky – volume: 5 start-page: 5410 year: 2021 end-page: 5414 ident: bib11 article-title: Combined ibrutinib and venetoclax treatment publication-title: Blood Adv contributor: fullname: Cretenet – volume: 87 year: 2021 ident: bib28 article-title: Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies publication-title: Blood Cells Mol Dis contributor: fullname: Sharma – volume: 24 start-page: 535 year: 2023 end-page: 552 ident: bib21 article-title: Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial publication-title: Lancet Oncol contributor: fullname: Bloor – volume: 12 year: 2021 ident: bib1 article-title: The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia publication-title: Ther Adv Hematol contributor: fullname: Danilov – volume: 395 start-page: 1278 year: 2020 end-page: 1291 ident: bib25 article-title: Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial publication-title: Lancet contributor: fullname: Jurczak – volume: 11 start-page: 39 year: 2021 ident: bib10 article-title: Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication publication-title: Blood Cancer J contributor: fullname: Franzen – volume: 139 start-page: 3278 year: 2022 end-page: 3289 ident: bib15 article-title: Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort publication-title: Blood contributor: fullname: Siddiqi – year: March 26, 2018 ident: bib17 article-title: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): chronic lymphocytic leukemia/small lymphocytic lymphoma, version 5 – volume: 37 start-page: 2722 year: 2019 end-page: 2729 ident: bib13 article-title: Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study publication-title: J Clin Oncol contributor: fullname: Brock – volume: 140 start-page: 112 year: 2022 end-page: 120 ident: bib5 article-title: Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial publication-title: Blood contributor: fullname: Hanson – volume: 107 start-page: 2108 year: 2022 end-page: 2120 ident: bib6 article-title: First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab publication-title: Haematologica contributor: fullname: Demirkan – volume: 41 start-page: 3689 year: 2023 end-page: 3699 ident: bib19 article-title: Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study publication-title: J Clin Oncol contributor: fullname: Owen – volume: 39 start-page: 3853 year: 2021 end-page: 3865 ident: bib12 article-title: Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study publication-title: J Clin Oncol contributor: fullname: Siddiqi – volume: 379 start-page: 2517 year: 2018 ident: 10.1016/S1470-2045(23)00452-7_bib7 article-title: Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL publication-title: N Engl J Med doi: 10.1056/NEJMoa1812836 contributor: fullname: Woyach – volume: 37 start-page: 2722 year: 2019 ident: 10.1016/S1470-2045(23)00452-7_bib13 article-title: Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study publication-title: J Clin Oncol doi: 10.1200/JCO.19.00894 contributor: fullname: Hillmen – volume: 24 start-page: 535 year: 2023 ident: 10.1016/S1470-2045(23)00452-7_bib21 article-title: Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(23)00144-4 contributor: fullname: Hillmen – volume: 131 start-page: 2745 year: 2018 ident: 10.1016/S1470-2045(23)00452-7_bib20 article-title: iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL publication-title: Blood doi: 10.1182/blood-2017-09-806398 contributor: fullname: Hallek – volume: 380 start-page: 2095 year: 2019 ident: 10.1016/S1470-2045(23)00452-7_bib14 article-title: Ibrutinib and venetoclax for first-line treatment of CLL publication-title: N Engl J Med doi: 10.1056/NEJMoa1900574 contributor: fullname: Jain – volume: 5 start-page: 5410 year: 2021 ident: 10.1016/S1470-2045(23)00452-7_bib11 article-title: Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia publication-title: Blood Adv doi: 10.1182/bloodadvances.2021004861 contributor: fullname: Kater – volume: 94 start-page: 1353 year: 2019 ident: 10.1016/S1470-2045(23)00452-7_bib4 article-title: Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma publication-title: Am J Hematol doi: 10.1002/ajh.25638 contributor: fullname: Munir – volume: 39 start-page: 3853 year: 2021 ident: 10.1016/S1470-2045(23)00452-7_bib12 article-title: Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study publication-title: J Clin Oncol doi: 10.1200/JCO.21.00807 contributor: fullname: Wierda – volume: 39 start-page: 215 year: 2021 ident: 10.1016/S1470-2045(23)00452-7_bib9 article-title: Obinutuzumab-related adverse events: a systematic review and meta-analysis publication-title: Hematol Oncol doi: 10.1002/hon.2828 contributor: fullname: Amitai – volume: 6 start-page: 3440 year: 2022 ident: 10.1016/S1470-2045(23)00452-7_bib2 article-title: Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia publication-title: Blood Adv doi: 10.1182/bloodadvances.2021006434 contributor: fullname: Barr – volume: 102 year: 2021 ident: 10.1016/S1470-2045(23)00452-7_bib27 article-title: Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia publication-title: Leuk Res doi: 10.1016/j.leukres.2021.106520 contributor: fullname: Solman – volume: 23 start-page: 818 year: 2022 ident: 10.1016/S1470-2045(23)00452-7_bib16 article-title: Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(22)00220-0 contributor: fullname: Kater – volume: 41 start-page: 3689 year: 2023 ident: 10.1016/S1470-2045(23)00452-7_bib19 article-title: Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study publication-title: J Clin Oncol doi: 10.1200/JCO.22.02283 contributor: fullname: Munir – volume: 395 start-page: 1278 year: 2020 ident: 10.1016/S1470-2045(23)00452-7_bib25 article-title: Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(20)30262-2 contributor: fullname: Sharman – ident: 10.1016/S1470-2045(23)00452-7_bib23 doi: 10.1097/01.HS9.0000969372.28228.42 – volume: 12 year: 2021 ident: 10.1016/S1470-2045(23)00452-7_bib1 article-title: The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia publication-title: Ther Adv Hematol doi: 10.1177/2040620721989588 contributor: fullname: Gordon – volume: 87 year: 2021 ident: 10.1016/S1470-2045(23)00452-7_bib28 article-title: Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies publication-title: Blood Cells Mol Dis doi: 10.1016/j.bcmd.2020.102525 contributor: fullname: Borah – volume: 2 start-page: 114 year: 2022 ident: 10.1016/S1470-2045(23)00452-7_bib26 article-title: Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients publication-title: Commun Med (Lond) doi: 10.1038/s43856-022-00178-5 contributor: fullname: Svanberg – ident: 10.1016/S1470-2045(23)00452-7_bib3 – volume: 139 start-page: 3278 year: 2022 ident: 10.1016/S1470-2045(23)00452-7_bib15 article-title: Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort publication-title: Blood doi: 10.1182/blood.2021014488 contributor: fullname: Tam – volume: 107 start-page: 2108 year: 2022 ident: 10.1016/S1470-2045(23)00452-7_bib6 article-title: First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial publication-title: Haematologica doi: 10.3324/haematol.2021.279012 contributor: fullname: Moreno – volume: 140 start-page: 112 year: 2022 ident: 10.1016/S1470-2045(23)00452-7_bib5 article-title: Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial publication-title: Blood doi: 10.1182/blood.2021014960 contributor: fullname: Shanafelt – volume: 39 start-page: 4049 year: 2021 ident: 10.1016/S1470-2045(23)00452-7_bib8 article-title: Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study publication-title: J Clin Oncol doi: 10.1200/JCO.21.01181 contributor: fullname: Al-Sawaf – volume: 11 start-page: 39 year: 2021 ident: 10.1016/S1470-2045(23)00452-7_bib10 article-title: Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication publication-title: Blood Cancer J doi: 10.1038/s41408-021-00429-z contributor: fullname: Lu – volume: 7 start-page: e811 year: 2022 ident: 10.1016/S1470-2045(23)00452-7_bib29 article-title: COVID-19 vaccination response and its practical application in patients with chronic lymphocytic leukemia publication-title: HemaSphere doi: 10.1097/HS9.0000000000000811 contributor: fullname: Shadman – volume: 140 start-page: 4137 issue: suppl 1 year: 2022 ident: 10.1016/S1470-2045(23)00452-7_bib22 article-title: Exploratory results of PET-CT and residual lymph node fine needle aspiration of patients treated with first-line venetoclax and ibrutinib for CLL/Sll; first interim analysis of the phase 2 HOVON 158/Next STEP trial publication-title: Blood doi: 10.1182/blood-2022-163209 contributor: fullname: Levin – volume: 370 start-page: 1101 year: 2014 ident: 10.1016/S1470-2045(23)00452-7_bib24 article-title: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions publication-title: N Engl J Med doi: 10.1056/NEJMoa1313984 contributor: fullname: Goede – volume: 1 year: 2022 ident: 10.1016/S1470-2045(23)00452-7_bib18 article-title: Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities publication-title: NEJM Evid doi: 10.1056/EVIDoa2200006 contributor: fullname: Kater |
| SSID | ssj0017105 |
| Score | 2.608538 |
| Snippet | In the GLOW study, fixed-duration ibrutinib–venetoclax showed superior progression-free survival versus chlorambucil–obinutuzumab in patients with previously... In the GLOW study, fixed-duration ibrutinib-venetoclax showed superior progression-free survival versus chlorambucil-obinutuzumab in patients with previously... Summary Background In the GLOW study, fixed-duration ibrutinib–venetoclax showed superior progression-free survival versus chlorambucil–obinutuzumab in... BackgroundIn the GLOW study, fixed-duration ibrutinib-venetoclax showed superior progression-free survival versus chlorambucil-obinutuzumab in patients with... |
| SourceID | hal proquest crossref pubmed elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 1423 |
| SubjectTerms | Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemotherapy Chlorambucil Chlorambucil - adverse effects Chlorambucil - therapeutic use Chronic lymphocytic leukemia Clinical decision making Clinical trials Comorbidity Creatinine Female Follow-Up Studies Humans Immunotherapy Inhibitor drugs Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Life Sciences Male Monoclonal antibodies Mutation Myelodysplastic syndrome Patients Pneumonia Pneumonia - chemically induced Survival Targeted cancer therapy |
| Title | Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial |
| URI | https://dx.doi.org/10.1016/S1470-2045(23)00452-7 https://www.ncbi.nlm.nih.gov/pubmed/37944541 https://www.proquest.com/docview/2894695770 https://www.proquest.com/docview/2889245854 https://inserm.hal.science/inserm-04777948 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3bbtQwELXYVkK8IO6ElpWRQGqlNc3FXie8oFJ1WaFSEFCxb5bjONqI3SRlY-jyxD_wZfwCX8LYyaZPhbcoVylzPHPGPp5B6CnjQOwZ4ySjlBLKVQJjjmkCXJlrxWTAUieQPR1Pz-ibGZt1E26rTla58YnOUWeVsnPkB5AYQCbHOPdf1ufEdo2yq6tdC40B2g5soLM7xY96iUfAWwljQLlPbNn1yx08Bx_7k3thtO8KixN-VWwazK1I8ioG6iLR5Ba62VFIfNja_Da6pss76PrbbpH8Lvo9KS50RjLTGhdDQgzoKov0z89f1rU1lVrIC2z1GGaF1RwydrlMjSoWcIPdDmYa88MsZYqLEtdWBlyZ1WKNTelU6TqDZ1xFXbxYAxYqtW7ssTZfpF4WEu-9Pnn3ef8FpmQNwwjngLTqOzE1tltZsMROw-hEoXqEbfcuAkjUixGGsJlVgDudjXA9h_CKI-y6itxDZ5PjT0dT0nVuIIpGfkNSXyehVhEHiKRURrbIWQaIiAJIgpmSiikNKIllkGuZ-Bn3FU-TlHMZ6pwqFd1HW2VV6ocIq0TGSoZc-eOYUg10KhhniQqDcR7mTOceer6xmajbAh2iV65ZIwtrZBFGwhlZcA_FG8uKjmW07EFAEPnfo88ACf1nbGXu6eGJKErwFkvhU87Bu8XfAg_tbrAiOpewEpcA9tCT_jL8VLtCI0sNpoR7YsiHIYOjHnrQYqz_WgTvpowGj_798h10IwQe1ipudtFW89Xox8CbmnSIBnzGh26IDNH2q-PT9x_-ApQ1GhM |
| link.rule.ids | 230,314,780,784,885,12056,12223,21388,27924,27925,31719,31720,33266,33267,33744,33745,43310,43579,43805,73745,74014,74302 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3bbtQwELXoVgJeENc2UMBIILXSmuZirxNeUEFdFtguCFrRN8txHG1ENglsDF2e-Ae-jF_gSxgn2fSp8BblKmWOZ87YxzMIPWYciD1jnCSUUkK5imDMMU2AK3OtmPRY3AhkZ6PJCX1zyk67CbdlJ6tc-8TGUSelsnPk-5AYQCbHOHefV1-I7RplV1e7FhobaNNWTmcDtPnicPb-Q7-OwFsRo0e5S2zh9fM9PPsf-5O7frDXlBYn_KLotDG3MsmLOGgTi8bX0bWOROKD1uo30CVd3ESXj7pl8lvo9zg70wlJTGteDCkx4KvI4j8_f1nnVpcql2fYKjLMEqs55OxyERuV5XCD3RBmavPDLGSMswJXVghcmmW-wqZodOk6gWeamro4XwEaSrWq7bE2n6VeZBLvvpq--7T3DFOygoGEU8Ba-Z2YCtvNLFjiRsXYyEL1ENv-XQSwqPMhhsCZlIA8nQxxNYcAiwPc9BW5jU7Gh8cvJ6Tr3UAUDdyaxK6OfK0CDiCJqQxsmbMEMBF4kAYzJRVTGnASSi_VMnIT7ioeRzHn0tcpVSq4gwZFWehthFUkQyV9rtxRSKkGQuWNkkj53ij1U6ZTBz1d20xUbYkO0WvXrJGFNbLwA9EYWXAHhWvLio5ntPxBQBj536NPAAn9Z2xt7snBVGQF-IuFcCnn4N_Cb56DdtZYEZ1TWIpzCDvoUX8Zfqpdo5GFBlPCPSFkxJDDUQdttRjrvxbAuymj3t1_v_whujI5PpqK6evZ23voqg-srNXf7KBB_dXo-8Ci6vhBN1T-AqJ2HCA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3NbtQwELboVqq4IP4JFDASSK20ZvNjrxMuqECXBZalAip6sxzH0UZkk8DG0OXEO_BkvAJPwjjJpqfCLUqcRMp8nvkm_jyD0EPGgdgzxklCKSWUqwjmHNMEuDLXikmPxY1Adj6eHtPXJ-yk0z-tOlnlxic2jjoplf1HPoLEADI5xrk7SjtZxNGLydPqC7EdpOxKa9dOYwttQ1R0_QHafnY4P3rfrynwVtDoUe4SW4T9bD_P6EN_cs8P9psy44SfF6m2FlYyeR4fbeLS5DK61BFKfNAi4Aq6oIuraOdtt2R-Df2eZKc6IYlpTY0hPQasFVn85-cv6-jqUuXyFFt1hllhtYD8XS5jo7IcBtjNYaY2P8xSxjgrcGVFwaVZ5WtsikajrhO4p6mvi_M1IKNU69oea_NZ6mUm8d7L2btP-08wJWuYVDgF3JXfiamw3diCJW4UjY1EVA-x7eVFAJc6H2IIokkJKNTJEFcLCLY4wE2PkevoeHL48fmUdH0ciAJD1CR2deRrFXAATExlYEueJYCPwIOUmCmpmNKAmVB6qZaRm3BX8TiKOZe-TqlSwQ00KMpC30JYRTJU0ufKHYeUaiBX3jiJlO-NUz9lOnXQ443NRNWW6xC9js0aWVgjCz8QjZEFd1C4sazoOEfLJQSElP_d-giQ0L_G1umeHsxEVoDvWAqXcg6-LvzmOWh3gxXROYiVOIOzgx70l-Gj2vUaWWgwJYwJITuGfI466GaLsf5tATybMurd_vfD76MdmCVi9mr-5g666ANBa6U4u2hQfzX6LhCqOr7XzZS_2YkgTQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fixed-duration+ibrutinib%E2%80%93venetoclax+versus+chlorambucil%E2%80%93obinutuzumab+in+previously+untreated+chronic+lymphocytic+leukaemia+%28GLOW%29%3A+4-year+follow-up+from+a+multicentre%2C+open-label%2C+randomised%2C+phase+3+trial&rft.jtitle=The+lancet+oncology&rft.au=Niemann%2C+Carsten+U&rft.au=Munir%2C+Talha&rft.au=Moreno%2C+Carol&rft.au=Owen%2C+Carolyn&rft.date=2023-12-01&rft.issn=1470-2045&rft.volume=24&rft.issue=12&rft.spage=1423&rft.epage=1433&rft_id=info:doi/10.1016%2FS1470-2045%2823%2900452-7&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_S1470_2045_23_00452_7 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1470-2045&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1470-2045&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1470-2045&client=summon |